Two-thirds of newly approved prescription drugs reviewed by the Institute for Clinical and Economic Review between 2022 and 2025 were launched at prices exceeding ICER's cost-effectiveness thresholds.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Drug pricing policy, insurance prior authorization, and essential drug shortages affecting medication affordability and access.